You are here

Article Text

Article menu
Download PDFPDF
Letter
Idiopathic thrombocytopenic purpura and the second dose of MMR
  1. Julia Stowe1,
  2. George Kafatos2,
  3. Nick Andrews2,
  4. Elizabeth Miller1
  1. 1
    Immunisation Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK
  2. 2
    Statistics, Modelling and Bioinformatics Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK
  1. Professor Elizabeth Miller, Immunisation Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK; liz.miller{at}hpa.org.uk

https://doi.org/10.1136/adc.2007.126003

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    An increase in idiopathic thrombocytopenic purpura (ITP) cases in the 6 weeks following the first dose of the measles, mumps and rubella (MMR) vaccine has been established, with absolute risks estimated as 1 in 22 3001 and 1 in 21 000 vaccine doses,2 with two in every three cases attributable to the vaccine. However, the risk after a second dose of MMR vaccine has not been investigated.

    Hospital admissions for children aged from 3 to <6 years with a discharge diagnosis of ITP (ICD-code D693 in any diagnosis field) were identified from computerised hospital episode data from North, East and South London, Essex, East Anglia, Sussex and Kent for the period from 1 April 1997 to 31 December 2005. These admissions were then linked to second MMR dose records held …

    View Full Text

    Footnotes

    • Competing interests: Support for the salary of J Stowe was provided by a grant from the Department of Health Research and Development Division (grant number 121/7470). No other conflicts of interest.